Yue Sheng1, Ying Song1, Zhigang Li1, Yabo Wang1, Heming Lin1, Hanhua Cheng2, Rongjia Zhou3. 1. Hubei Key Laboratory of Cell Homoeostasis, College of Life Sciences, Wuhan University, Wuhan, 430072, P. R. China. 2. Hubei Key Laboratory of Cell Homoeostasis, College of Life Sciences, Wuhan University, Wuhan, 430072, P. R. China. hhcheng@whu.edu.cn. 3. Hubei Key Laboratory of Cell Homoeostasis, College of Life Sciences, Wuhan University, Wuhan, 430072, P. R. China. rjzhou@whu.edu.cn.
Abstract
Intracellular membrane trafficking is essential for eukaryotic cell existence. Here, we show that RAB37 activation through GTP binding recruits ATG5-12 to isolation membrane and promotes autophagosome formation through the ATG5-ATG12-ATG16L1 complex. RAB37 is localized on the isolation membrane. It can bind directly with ATG5 and promotes formation of the ATG5-12-16 complex. Mutation analysis reveals that GTP-bound RAB37 exhibits an enhanced interaction with ATG5-12 and GDP-stabilised mutation impairs the interaction. RAB37 promotes ATG5-12 interaction with ATG16L1, thus facilitates lipidation of LC3B in a GTP-dependent manner to enhance autophagy. Notably, ablation of RAB37 expression affects the complex formation and decreases autophagy, whereas forced RAB37 expression promotes autophagy and also suppresses cell proliferation. Our results demonstrate a role of RAB37 in autophagosome formation through a molecular connection of RAB37, ATG5-12, ATG16L1 up to LC3B, suggesting an organiser role of RAB37 during autophagosomal membrane biogenesis. These findings have broad implications for understanding the role of RAB vesicle transport in autophagy and cancer.
Intracellular membrane trafficking is essential for eukaryotic cell existence. Here, we show that RAB37 activation through GTP binding recruits ATG5-12 to isolation membrane and promotes autophagosome formation through the ATG5-ATG12-ATG16L1 complex. RAB37 is localized on the isolation membrane. It can bind directly with ATG5 and promotes formation of the ATG5-12-16 complex. Mutation analysis reveals that GTP-bound RAB37 exhibits an enhanced interaction with ATG5-12 and GDP-stabilised mutation impairs the interaction. RAB37 promotes ATG5-12 interaction with ATG16L1, thus facilitates lipidation of LC3B in a GTP-dependent manner to enhance autophagy. Notably, ablation of RAB37 expression affects the complex formation and decreases autophagy, whereas forced RAB37 expression promotes autophagy and also suppresses cell proliferation. Our results demonstrate a role of RAB37 in autophagosome formation through a molecular connection of RAB37, ATG5-12, ATG16L1 up to LC3B, suggesting an organiser role of RAB37 during autophagosomal membrane biogenesis. These findings have broad implications for understanding the role of RAB vesicle transport in autophagy and cancer.
Intracellular membrane trafficking between organelles is essential for nearly all eukaryotic cells. The process involves vesicle budding, motility, tethering and fusion with the specific target membrane. The organisation and transport of membrane organelles ensure different molecules or cell parts with different biochemical natures to be sequestered and allow for the exchange of the materials between compartments. As key organisers of these processes, RAB GTPases regulate membrane functions through a switch between two distinct conformations: the GTP-bound “on” and the GDP-bound “off” forms [1]. Membrane trafficking regulation has both physiological and pathological implications. RAB pathway dysfunctions are associated with many human diseases, such as cancer [2], mental retardation [3], Parkinson’s disease [4], immunodeficiency [5] and obesity [6].The RAB family consists of small GTPases and is a part of the RAS superfamily. At least 60 RAB members have been identified in humans [1]. RABGTP proteins (active) localized in membranes can recruit specific effector proteins to target membranes, whereas RABGDP proteins (inactive) disassociate from the membrane to the cytosol and are recycled. A number of RAB proteins are involved in autophagy regulation, especially in the processes of autophagosome formation and autophagosome–lysosome fusion [7]. For example, Ypt1, a homologue of RAB1 in yeast, can interact with Atg11 and is required for autophagosome formation in a GTP-dependent manner [8]. It can also regulate autophagy by recruiting its effector Atg1 [9]. Ypt6 participates proper traffic of Atg9 to the preautophagosomal structure under a high temperature stress [10]. Knockdown of RAB1b and RAB2 increases levels of the key autophagic protein LC3B-II [4]. RAB26 and RAB33B are required for isolation membrane formation by interaction with ATG16L1 [11, 12]. Rab19 can directly bind to Atg16 in a GTP-dependent manner to promote intestinal secretory cell differentiation in Drosophila [13]. In addition, some other RAB members are involved in maturation of autophagic vacuoles, such as RAB7, RAB8B and Rab2 (Drosophila) [14-17]. Despite these progresses, however, the molecular mechanisms and the spatiotemporal regulations of the crosstalk between GTPases and autophagy remain largely unknown.RAB37 is localized on various vesicles related to secretion and exocytosis, including secretory granules in bone marrow mast cells [18], dense-core vesicles in PC12 cells [19], insulin secretory granules [20] and Weibel-Palade bodies (endothelial-cell-specific organelles) [21]. RAB37 regulates mast cell degranulation through its effector protein [22], TNF-alpha secretion from activated macrophages [23] and insulin secretion through exocytosis [24]. RAB37 is also associated with endothelial cell function and embryogenesis in zebrafish [25]. In addition, RAB37 is involved in tumour cell growth [26-29]. A recent study indicated that RAB37 can suppress metastasis through the TIMP1-MMP9 pathway [30], highlighting an importance of RAB37 protein in cancer. Despite these research efforts, possible association of RAB37 with autophagy and its regulation mechanisms remain unclear.In this study, in an attempt to better understand the functions and molecular mechanisms of RAB37 in autophagy, we investigate ATG proteins interacting with RAB37 and find that RAB37 as a key organiser of autophagosome formation promotes autophagy through the ATG5-ATG12-ATG16L1 complex. It binds directly with ATG5, and promotes autophagosome formation in a GTP-dependent manner. RAB37 knockdown can decrease autophagy and increase tumour metastasis in vivo. Our results provide clear evidence and underlying molecular mechanism that RAB37 promotes autophagy. These findings have broad implications for understanding the role of RAB37 vesicle transport in autophagy and cancer.
Results
RAB37 directly interacts with ATG5
To investigate whether RAB37 is involved in autophagy, we detected RAB37 interaction with key autophagy protein ATG5. Co-immunoprecipitation experiments showed that RAB37 was associated with ATG5 and ATG5-12 (Fig. 1a). To map interactive domains of ATG5 with RAB37, we used deletion mapping and reciprocal co-immunoprecipitation analysis, which revealed that the L2-UblB of ATG5 was main domain to interact with RAB37 (Fig. 1b-d). To further explore whether the interaction was direct or indirect, yeast two-hybrid and GST-pulldown assays were used. The L2-UblB domain in the C-terminal of ATG5 showed a direct interaction with RAB37 after test of various deletion variants, while RAB37 did not directly interact with ATG12. Yeast two-hybrid assay indicated the direct binding between RAB37 and ATG5 (Fig. 1e). As GTP-γ-S is a non-hydrolyzable GTP analogue, we used GTPγS assay to investigate whether RAB37 interaction with ATG5 is dependent on its GTP-binding function. GTPγS assay showed that the direct interaction depended on GTP-binding of RAB37 (Fig. 1f and Supplementary Fig. S1). Confocal fluorescence microscopy showed that obvious co-localization of CHERRY-RAB37 and ATG5-GFP puncta were detected when co-transfected upon starvation induction (Fig. 1g). ATG5 truncated mutants (-C and -E) have stronger interactions with RAB37 in comparison with full-length ATG5, which may reflect an appropriate topological structure of ATG5 domain interaction with RAB37. These data suggested that RAB37 directly interacts with ATG5.
Fig. 1
RAB37 directly interacts with ATG5. a Co-immunoprecipitation analysis between endogenous RAB37 and ATG5 in 293T cells. The lysates were immunoprecipitated with anti-ATG5, anti-RAB37 antibody or negative serum respectively, followed by immunoblotting with the anti-RAB37 or anti-ATG5 antibody respectively. b A schematic diagram of human ATG5 wild type and deletion mutants. The conserved domains (α1, UblA, L1, HR, L2 and Ub1B) are indicated in wild type ATG5. c, d Interactions of RAB37 with ATG5 mutants. 293T cells were transiently co-transfected with FLAG-RAB37 and MYC-GFP-ATG5 mutants or ATG5 wild type. Cell lysates were examined by Western blotting using an anti-GFP or anti-FLAG antibody. For co-immunoprecipitation assays, the lysates were immunoprecipitated with an anti-GFP antibody followed by immunoblotting with an anti-FLAG or anti-GFP antibody (c), or immunoprecipitated with an anti-FLAG antibody followed by immunoblotting with an anti-GFP or anti-FLAG antibody (d). e Identification of the interaction between RAB37 and ATG5 by yeast two-hybrid assay. Y2HGold cells were transformed with plasmids as indicated. The growth of yeast colonies containing relevant plasmids on SD/-His/-Leu/-Trp medium showed that RAB37 interacted with wild-type ATG5, and the truncated ATG5-C and -E in yeast cells. AD, pGADT7; BD, pGBKT7. f In vitro GST-pulldown assay showed interaction of RAB37 with ATG5 and ATG12, which was dependent on GTP binding activity of RAB37. GST-ATG5, GST-ATG5-C, GST-ATG5-E, and GST-ATG12 were incubated with His-tagged RAB37 respectively, when present of GTPγS or not. Proteins pulled down with glutathione-agarose were subjected to SDS-PAGE followed by immunoblotting with an anti-RAB37 antibody. Bottom: total proteins per lane were determined by the Pierce BCA protein assay kit. g Co-localization of RAB37 puncta with ATG5. COS-7 cells were co-transfected with CHERRY-RAB37 and ATG5-GFP. Before fixation, the cells were cultured in starvation medium EBSS for 1 h. Co-localization dots were observed between CHERRY-RAB37 and ATG5-GFP as indicated in arrowheads. Square areas in white line were enlarged. Images were captured using confocal microscopy. The nuclei were counterstained with DAPI (blue). Percentage of co-localized dots (CHERRY-RAB37 + ATG5-GFP (yellow) / ATG5-GFP (green)) upon starvation was determined in comparison with non-starvation controls. Data are presented as means ± S.D. * stands for P < 0.05 (n = 3 independent experiments). Scale bar, 10 µm
RAB37 directly interacts with ATG5. a Co-immunoprecipitation analysis between endogenous RAB37 and ATG5 in 293T cells. The lysates were immunoprecipitated with anti-ATG5, anti-RAB37 antibody or negative serum respectively, followed by immunoblotting with the anti-RAB37 or anti-ATG5 antibody respectively. b A schematic diagram of humanATG5 wild type and deletion mutants. The conserved domains (α1, UblA, L1, HR, L2 and Ub1B) are indicated in wild type ATG5. c, d Interactions of RAB37 with ATG5 mutants. 293T cells were transiently co-transfected with FLAG-RAB37 and MYC-GFP-ATG5 mutants or ATG5 wild type. Cell lysates were examined by Western blotting using an anti-GFP or anti-FLAG antibody. For co-immunoprecipitation assays, the lysates were immunoprecipitated with an anti-GFP antibody followed by immunoblotting with an anti-FLAG or anti-GFP antibody (c), or immunoprecipitated with an anti-FLAG antibody followed by immunoblotting with an anti-GFP or anti-FLAG antibody (d). e Identification of the interaction between RAB37 and ATG5 by yeast two-hybrid assay. Y2HGold cells were transformed with plasmids as indicated. The growth of yeast colonies containing relevant plasmids on SD/-His/-Leu/-Trp medium showed that RAB37 interacted with wild-type ATG5, and the truncated ATG5-C and -E in yeast cells. AD, pGADT7; BD, pGBKT7. f In vitro GST-pulldown assay showed interaction of RAB37 with ATG5 and ATG12, which was dependent on GTP binding activity of RAB37. GST-ATG5, GST-ATG5-C, GST-ATG5-E, and GST-ATG12 were incubated with His-tagged RAB37 respectively, when present of GTPγS or not. Proteins pulled down with glutathione-agarose were subjected to SDS-PAGE followed by immunoblotting with an anti-RAB37 antibody. Bottom: total proteins per lane were determined by the Pierce BCA protein assay kit. g Co-localization of RAB37 puncta with ATG5. COS-7 cells were co-transfected with CHERRY-RAB37 and ATG5-GFP. Before fixation, the cells were cultured in starvation medium EBSS for 1 h. Co-localization dots were observed between CHERRY-RAB37 and ATG5-GFP as indicated in arrowheads. Square areas in white line were enlarged. Images were captured using confocal microscopy. The nuclei were counterstained with DAPI (blue). Percentage of co-localized dots (CHERRY-RAB37 + ATG5-GFP (yellow) / ATG5-GFP (green)) upon starvation was determined in comparison with non-starvation controls. Data are presented as means ± S.D. * stands for P < 0.05 (n = 3 independent experiments). Scale bar, 10 µm
RAB37 interacts with ATG5 in a GTP-dependent manner
To test whether RAB37 functions as a GTPase, we used two RAB37 mutants, a GTP-hydrolysis-deficient, constitutively active mutant (RAB37-Q89L) and a GDP-stabilised, constitutively negative mutant (RAB37-T43N) (Fig. 2a), and tested effects of ATG5 interaction with the RAB37 mutants. As RAB37 is a novel GTPase, we first detected the GTPase activity of RAB37 and its mutants. Protein quantification was determined by Pierce BCA protein assay in these GTPase activity experiments (Fig. 2b, c). RAB37 wild type showed an obvious dephosphorylation from GTP, in comparison with two RAB37 mutants (RAB37-Q89L had a constantly binding with GTP and RAB37-T43N did not bind with GTP) (Fig. 2d, e). Co-immunoprecipitation experiments showed that the RAB37-Q89L mutant had an obvious interaction with ATG5 upon starvation induction, whereas the RAB37-T43N mutant was scarcely associated with ATG5 (Fig. 2f). Confocal fluorescence microscopy showed that RAB37 transfection promotes formation of ATG5 positive puncta in a GTP-dependent manner (Fig. 2g). Together, these data suggested that RAB37 interacts with ATG5 in a GTP-dependent manner.
Fig. 2
RAB37 interacts with ATG5 in a GTP-dependent manner. a A schematic representation of the RAB37 mutants. Inactive RAB37-T43N is a GDP-stabilised mutant, and active RAB37-Q89L is a GTP-stabilised mutant. b, c Protein quantification was determined by Pierce BCA protein assay kit. Three RAB37 proteins (wild type and two mutants) were purified from E. coli. d, e RAB37 (and its mutants -Q89L and -T43N) GTPase activity assays by Quantichrome ATPase/GTPase assay kit according to a standard curve. f RAB37 interacts with ATG5 in a GTP-dependent manner. MYC-ATG5 was transiently co-transfected with FLAG-RAB37-WT, FLAG-RAB37-T43N, FLAG-RAB37-Q89L or control plasmid into 293T cells respectively. For co-immunoprecipitation, the lysates were immunoprecipitated with an anti-FLAG antibody followed by immunoblotting with an anti-MYC and anti-FLAG antibodies. GAPDH was used as an internal control. g RAB37 transfection promotes formation of ATG5 positive puncta in a GTP-dependent manner. COS-7 cells transfected with CHERRY-RAB37-WT, CHERRY-RAB37-Q89L, CHERRY-RAB37-T43N or control vector pSico-CHERRY respectively. Left: representative images of cells with ATG5-GFP (green) and CHERRY-RAB37 (its mutants or control vector CHERRY, red). Right: ATG5 positive dots were quantified from ~20 cells. Data are presented as means ± S.D. * stands for P < 0.05, ** stands for P < 0.01 (n = 3 independent experiments)
RAB37 interacts with ATG5 in a GTP-dependent manner. a A schematic representation of the RAB37 mutants. Inactive RAB37-T43N is a GDP-stabilised mutant, and active RAB37-Q89L is a GTP-stabilised mutant. b, c Protein quantification was determined by Pierce BCA protein assay kit. Three RAB37 proteins (wild type and two mutants) were purified from E. coli. d, e RAB37 (and its mutants -Q89L and -T43N) GTPase activity assays by Quantichrome ATPase/GTPase assay kit according to a standard curve. f RAB37 interacts with ATG5 in a GTP-dependent manner. MYC-ATG5 was transiently co-transfected with FLAG-RAB37-WT, FLAG-RAB37-T43N, FLAG-RAB37-Q89L or control plasmid into 293T cells respectively. For co-immunoprecipitation, the lysates were immunoprecipitated with an anti-FLAG antibody followed by immunoblotting with an anti-MYC and anti-FLAG antibodies. GAPDH was used as an internal control. g RAB37 transfection promotes formation of ATG5 positive puncta in a GTP-dependent manner. COS-7 cells transfected with CHERRY-RAB37-WT, CHERRY-RAB37-Q89L, CHERRY-RAB37-T43N or control vector pSico-CHERRY respectively. Left: representative images of cells with ATG5-GFP (green) and CHERRY-RAB37 (its mutants or control vector CHERRY, red). Right: ATG5 positive dots were quantified from ~20 cells. Data are presented as means ± S.D. * stands for P < 0.05, ** stands for P < 0.01 (n = 3 independent experiments)
RAB37 localization on autophagosome in a GTP-dependent manner
To further investigate the RAB37 functions in autophagy, we explored whether RAB37 localizes on autophagosome upon starvation induction. Immunofluorescence and confocal fluorescence microscopy analyses showed co-localization of endogenous RAB37 with LC3B puncta upon starvation induction (Fig. 3a). Localization of RAB37 on autophagosome, mainly around its membrane, was further determined by immuno-EM analysis (Fig. 3b). Co-localization of RAB37-Q89L or RAB37-wild type with LC3B were further observed, whereas a marked reduction of co-localization was detected when the RAB37-T43N mutant was co-transfected (Fig. 3c-e). These results indicated that RAB37 localization on autophagosome is in a GTP-dependent manner.
Fig. 3
RAB37 co-localization with LC3B puncta upon starvation induction. a Puncta co-localization of endogenous RAB37 with LC3B upon starvation induction. COS-7 cells were cultured in normal or starvation medium EBSS for 1 h. Percentage of co-localized dots (RAB37 + LC3B (yellow) / LC3B (green)) upon starvation was quantified in comparison with non-starvation controls. Data are presented as means ± S.D. * stands for P < 0.05 (n = 3 independent experiments). Scale bar, 10 µm. b Localization of RAB37 puncta on autophagosome revealed by immuno-EM. HeLa cells were transiently transfected with pCMV-Tag2B or FLAG-RAB37, respectively. The cells were cultured in starvation medium EBSS for 1 h and examined using anti-FLAG antibody and then anti-mouse IgG conjugated to 6 nm gold particles. (i) Negative control, (ii) representative image of the localization of RAB37 puncta on autophagosome, and square areas in black line were enlarged and showed in (iii). Red triangles, gold particles; red arrowheads, the double membranes of autophagosome; Scale bar, 200 nm. c A schematic representation of the RAB37 mutants used in (d). RAB37-T43N is a GDP-stabilised mutant, and RAB37-Q89L is a GTP-stabilised mutant. d RAB37-Q89L promotes its co-localization with LC3B upon starvation induction. COS-7 cells were transiently co-transfected with RFP-LC3B and GFP-RAB37-T43N, -RAB37-Q89L or -WT respectively. The cells were cultured in starvation medium EBSS for 1 h and then examined using confocal microscopy. Non-starvation treatment was used as a control. Co-localizing structures are indicated in arrowheads. Square areas in the inset were enlarged. e Counting of co-localized puncta between RAB37 and LC3B per cell. Percentages of co-localized dots (RFP-LC3B + GFP-RAB37-WT, -Q89L or -T43N (yellow) / RFP-LC3B (red)) upon starvation were determined in comparison with non-starvation treatments. The co-localized dots were counted from ~30 cells. * stands for P < 0.05
RAB37 co-localization with LC3B puncta upon starvation induction. a Puncta co-localization of endogenous RAB37 with LC3B upon starvation induction. COS-7 cells were cultured in normal or starvation medium EBSS for 1 h. Percentage of co-localized dots (RAB37 + LC3B (yellow) / LC3B (green)) upon starvation was quantified in comparison with non-starvation controls. Data are presented as means ± S.D. * stands for P < 0.05 (n = 3 independent experiments). Scale bar, 10 µm. b Localization of RAB37 puncta on autophagosome revealed by immuno-EM. HeLa cells were transiently transfected with pCMV-Tag2B or FLAG-RAB37, respectively. The cells were cultured in starvation medium EBSS for 1 h and examined using anti-FLAG antibody and then anti-mouse IgG conjugated to 6 nm gold particles. (i) Negative control, (ii) representative image of the localization of RAB37 puncta on autophagosome, and square areas in black line were enlarged and showed in (iii). Red triangles, gold particles; red arrowheads, the double membranes of autophagosome; Scale bar, 200 nm. c A schematic representation of the RAB37 mutants used in (d). RAB37-T43N is a GDP-stabilised mutant, and RAB37-Q89L is a GTP-stabilised mutant. d RAB37-Q89L promotes its co-localization with LC3B upon starvation induction. COS-7 cells were transiently co-transfected with RFP-LC3B and GFP-RAB37-T43N, -RAB37-Q89L or -WT respectively. The cells were cultured in starvation medium EBSS for 1 h and then examined using confocal microscopy. Non-starvation treatment was used as a control. Co-localizing structures are indicated in arrowheads. Square areas in the inset were enlarged. e Counting of co-localized puncta between RAB37 and LC3B per cell. Percentages of co-localized dots (RFP-LC3B + GFP-RAB37-WT, -Q89L or -T43N (yellow) / RFP-LC3B (red)) upon starvation were determined in comparison with non-starvation treatments. The co-localized dots were counted from ~30 cells. * stands for P < 0.05
RAB37 promotes formation of the ATG5-12-16L1 complex in a GTP-dependent manner
To test a possible role of RAB37 in formation of the ATG5-12-16L1 complex, we established RAB37 knockdown HeLa cell lines (Supplementary Fig. S2a). Co-immunoprecipitation experiments showed that ATG5 interacted with RAB37 and ATG16L1 respectively, and RAB37 knockdown inhibited interaction of the ATG5-12 with ATG16L1 (Fig. 4a). Immunofluorescence analysis of endogenous ATG5 and ATG16L1 in the cells also revealed that RAB37 knockdown inhibited ATG5 co-localization with ATG16L1, while RAB37 forced expression promoted the co-localization (Fig. 4b). We further investigated effect of RAB37 on formation of the ATG5-12-16L1 complex. Sucrose density gradient centrifugation of the cell lysates and Western blot analysis showed that knockdown of RAB37 decreased molecular weight of the complex ATG5-12-16L1, while RAB37 overexpression promoted the complex formation (Fig. 4c). These data suggested a role of RAB37 in formation of the ATG5-12-16L1 complex.
Fig. 4
RAB37 knockdown interferes with formation of ATG12-ATG5-ATG16L1 complex. a ATG5 interacts with RAB37 and ATG16L1 respectively. Two cell lines (RAB37 knockdown and control HeLa cells) were cultured and then starved for 1 h before harvest. The lysates were immunoprecipitated with anti-ATG5 antibody or negative serum, followed by immunoblotting with the anti-RAB37, anti-ATG16L1 or anti-ATG5 antibody. b RAB37 knockdown interferes with co-localization of endogenous ATG5 and ATG16L1 proteins. RAB37 overexpression, RAB37 knockdown and wild type HeLa cells were starved in the medium EBSS for 1 h before stained by immuno fluorescence with anti-ATG5, anti-ATG16L1 antibodies and then anti-mouse IgG FITC conjugated antibody (green), or anti-rabbit IgG TRITC conjugated antibody (red) respectively. The nuclei were counterstained with DAPI (blue). Confocal images were taken. Scale bar, 10 µm. Percentages of co-localized dots (ATG5 + ATG16L1 (yellow)/ATG5 (green)) in three HeLa cell lines were determined and the co-localized dots between ATG5 and ATG16L1 were counted from ~15 cells respectively. * stands for P < 0.05. c RAB37 knockdown affects formation of ATG12-ATG5-ATG16L1 complex. Lysates of three cell lines (RAB37 overexpression, RAB37 knockdown and wild type HeLa cells) were separated using continuous sucrose gradients (0–30%). Fractions were subjected to Western blotting using the indicated antibodies. Red triangles indicate the size shift of the complex
RAB37 knockdown interferes with formation of ATG12-ATG5-ATG16L1 complex. a ATG5 interacts with RAB37 and ATG16L1 respectively. Two cell lines (RAB37 knockdown and control HeLa cells) were cultured and then starved for 1 h before harvest. The lysates were immunoprecipitated with anti-ATG5 antibody or negative serum, followed by immunoblotting with the anti-RAB37, anti-ATG16L1 or anti-ATG5 antibody. b RAB37 knockdown interferes with co-localization of endogenous ATG5 and ATG16L1 proteins. RAB37 overexpression, RAB37 knockdown and wild type HeLa cells were starved in the medium EBSS for 1 h before stained by immuno fluorescence with anti-ATG5, anti-ATG16L1 antibodies and then anti-mouse IgG FITC conjugated antibody (green), or anti-rabbit IgG TRITC conjugated antibody (red) respectively. The nuclei were counterstained with DAPI (blue). Confocal images were taken. Scale bar, 10 µm. Percentages of co-localized dots (ATG5 + ATG16L1 (yellow)/ATG5 (green)) in three HeLa cell lines were determined and the co-localized dots between ATG5 and ATG16L1 were counted from ~15 cells respectively. * stands for P < 0.05. c RAB37 knockdown affects formation of ATG12-ATG5-ATG16L1 complex. Lysates of three cell lines (RAB37 overexpression, RAB37 knockdown and wild type HeLa cells) were separated using continuous sucrose gradients (0–30%). Fractions were subjected to Western blotting using the indicated antibodies. Red triangles indicate the size shift of the complexGel filtration was used further to determine the role of RAB37 in ATG12-ATG5-ATG16L1 complex assembly. RAB37 knockdown interfered with formation of ~800 kDa multimeric ATG protein complex including eight sets of ATG5-12-16L1, even lead to monomer ATG5-12 and ATG16L1 (Fig. 5a-c). We also investigated whether the complex formation is dependent on GTP-binding of RAB37. The GTP-hydrolysis-deficient, constitutively active mutant (RAB37-Q89L) can increase molecular size of the complex ATG5-12-16L1, while constitutively negative mutant (RAB37-T43N) affected the complex formation (Fig. 5a-c). These data indicated that RAB37 promotes formation of the ATG5-12-16L1 complex in a GTP-dependent manner, thus facilitates lipidation of LC3B at initiation of autophagosome formation (Fig. 5d).
Fig. 5
RAB37 promotes formation of the ATG12-ATG5-ATG16L1 complex in a GTP-dependent manner. a–c Gel-filtration analysis of the ATG12-ATG5-ATG16L1 complex by chromatography. Cell lysates of three cell lines (RAB37 overexpression, RAB37 knockdown and control HeLa cells) and two transiently transfected cells (FLAG-RAB37-Q89L and FLAG-RAB37-T43N) were separated by size-exclusion chromatography. Fractions were subjected to Western blotting with anti-ATG16L1 (a), anti-ATG5 (b) or anti-RAB37 antibody (c), respectively. The positions of the molecular mass standards in chromatography are showed in arrows. d Work model of RAB37 function together with ATG5-12 and ATG16L1 for autophagy
RAB37 promotes formation of the ATG12-ATG5-ATG16L1 complex in a GTP-dependent manner. a–c Gel-filtration analysis of the ATG12-ATG5-ATG16L1 complex by chromatography. Cell lysates of three cell lines (RAB37 overexpression, RAB37 knockdown and control HeLa cells) and two transiently transfected cells (FLAG-RAB37-Q89L and FLAG-RAB37-T43N) were separated by size-exclusion chromatography. Fractions were subjected to Western blotting with anti-ATG16L1 (a), anti-ATG5 (b) or anti-RAB37 antibody (c), respectively. The positions of the molecular mass standards in chromatography are showed in arrows. d Work model of RAB37 function together with ATG5-12 and ATG16L1 for autophagy
RAB37 puncta are co-localized with isolation membranes in an ATG5 dependent manner
To confirm the association of RAB37 puncta with isolation membranes, we used RAB37-Q89L and RAB37-T43N mutants to analyse co-localization of RAB37 puncta with ATG5 and an omegasome marker DFCP1 (Double FYVE-containing protein 1, a PtdIns(3)P-binding ER protein). Confocal images showed that RAB37-Q89L puncta were co-localized with DFCP1 and ATG5 upon starvation induction, whereas the co-localization was markedly reduced when RAB37 was functionally mutated in constitutively negative mutation (Fig. 6a, b). Notably, most RAB37/ATG5 positive structures were DFCP1 positive (Fig. 6c), indicating that RAB37 is co-localized with isolation membranes. We further investigate whether ATG5 interference influences the RAB37 co-localization with DFCP1. Confocal fluorescence microscopy analyses showed that ATG5 knockdown significantly prevented the RAB37 co-localization with DFCP1 (Fig. 6d, e). The results suggested that RAB37 puncta are co-localized with isolation membranes in an ATG5 dependent manner.
Fig. 6
RAB37 puncta are co-localized with isolation membranes. a Co-localization of RAB37 puncta with ATG5 and an omegasome marker DFCP1. COS-7 cells were co-transfected with RAB37 mutants (GFP-RAB37-Q89L and -RAB37-T43N) and CHERRY-mDFCP1. The cells were starved in the medium EBSS for 1 h befor harvest. Endogenous ATG5 protein was stained by immune fluorescence using anti-ATG5 antibody and then anti-rabbit IgG AMCA conjugated antibody (blue). Confocal images were taken. Scale bar, 10 µm. The outlined region is magnified in the inset. b ATG5 co-localizations with RAB37-Q89L, RAB37-T43N and DFCP1, respectively. GFP-ATG5 was co-transfected with CHERRY-RAB37-Q89L, CHERRY-RAB37-T43N and CHERRY-DFCP1 in HeLa cells, respectively. Scale bar, 10 µm. c Representative images of DFCP1-positive, RAB37-Q89L/DFCP1/ATG5-positive, RAB37-Q89L/ATG5-positive and ATG5-positive puncta in COS-7 cells from (a). Positive dots were quantified from ~20 cells. Scale bar, 1 µm. Data are presented as means ± S.D. * stands for P < 0.05, ** stands for P < 0.01 (n = 3 independent experiments). d Determination of effective ATG5 siRNA. Three siRNAs and a negative control siRNA were transfected into HeLa cells, and ATG5 and ATG5-12 protein levels were analysed by Western blots. e ATG5 interference inhibits RAB37 co-localization with CHERRY-mDFCP1. HeLa cells were co-transfected with siRNA (siR-ATG5 1# or negative control), GFP-RAB37 and CHERRY-mDFCP1. The cells were cultured in DMEM with 10% FBS and starved in starvation medium EBSS for 1 h. The images were taken under confocal microscopy. Scale bar, 10 µm. Percentage of co-localized dots (GFP-RAB37 + CHERRY-mDFCP1 (yellow) / CHERRY-mDFCP1 (red)) in controls were determined in comparison with ATG5 knockdown treatments. The co-localized dots were counted from ~20 cells. * stands for P < 0.05
RAB37 puncta are co-localized with isolation membranes. a Co-localization of RAB37 puncta with ATG5 and an omegasome marker DFCP1. COS-7 cells were co-transfected with RAB37 mutants (GFP-RAB37-Q89L and -RAB37-T43N) and CHERRY-mDFCP1. The cells were starved in the medium EBSS for 1 h befor harvest. Endogenous ATG5 protein was stained by immune fluorescence using anti-ATG5 antibody and then anti-rabbit IgG AMCA conjugated antibody (blue). Confocal images were taken. Scale bar, 10 µm. The outlined region is magnified in the inset. b ATG5 co-localizations with RAB37-Q89L, RAB37-T43N and DFCP1, respectively. GFP-ATG5 was co-transfected with CHERRY-RAB37-Q89L, CHERRY-RAB37-T43N and CHERRY-DFCP1 in HeLa cells, respectively. Scale bar, 10 µm. c Representative images of DFCP1-positive, RAB37-Q89L/DFCP1/ATG5-positive, RAB37-Q89L/ATG5-positive and ATG5-positive puncta in COS-7 cells from (a). Positive dots were quantified from ~20 cells. Scale bar, 1 µm. Data are presented as means ± S.D. * stands for P < 0.05, ** stands for P < 0.01 (n = 3 independent experiments). d Determination of effective ATG5 siRNA. Three siRNAs and a negative control siRNA were transfected into HeLa cells, and ATG5 and ATG5-12 protein levels were analysed by Western blots. e ATG5 interference inhibits RAB37 co-localization with CHERRY-mDFCP1. HeLa cells were co-transfected with siRNA (siR-ATG5 1# or negative control), GFP-RAB37 and CHERRY-mDFCP1. The cells were cultured in DMEM with 10% FBS and starved in starvation medium EBSS for 1 h. The images were taken under confocal microscopy. Scale bar, 10 µm. Percentage of co-localized dots (GFP-RAB37 + CHERRY-mDFCP1 (yellow) / CHERRY-mDFCP1 (red)) in controls were determined in comparison with ATG5 knockdown treatments. The co-localized dots were counted from ~20 cells. * stands for P < 0.05
RAB37-associated autophagy flux
To investigate RAB37-associated autophagy process, we tested the RAB37-involved autophagy flux through RAB37 RNAi and forced expression. Western blot analysis showed that RAB37 knockdown inhibited LC3B-II formation, whereas overexpression promoted the formation in the cell line upon starvation induction, and LC3B-II was accumulated during bafilomycin A1 treatment (Fig. 7a). In addition, autophagic substrate SQSTM1 level had a corresponding change with LC3B-II (Fig. 7b). Autophagy flux tests were further performed using a tandem fluorescent indicator, mCherry-GFP-LC3, in RAB37 stable overexpression and knockdown cell lines. Since green fluorescence of the fusion protein is very sensitive to the acidic environment of lysosomes and quickly quenched in autolysosomes, just red fluorescence could be detected in the autolysosomes [31, 32]. Fluorescence analysis using the tandem fluorescent indicator system in these cell lines showed that RAB37 knockdown significantly inhibited formation of autophagosomes, while overexpression promotes the formation. Further bafilomycin A1 treatment showed a significant accumulation of autophagosomes in RAB37 overexpression (Fig. 7c, d). Together, these data demonstrate that RAB37 promotes formation of autophagosomes, but does not affect its degradation process through lysosomes, upon starvation induction.
Fig. 7
RAB37-associated autophagy flux. a, b RAB37 knockdown inhibits and over-expression promotes LC3B-II formation. Bafilomycin A1 treatment results in protein accumulation of LC3B-II and SQSTM1. RAB37 overexpression, RAB37 knockdown and control HeLa cells were cultured and then starved in EBSS with or without bafilomycin A1 (100 nM) for 1 h. The cell lysates were analysed by immunoblotting with antibodies as indicated. GAPDH was used as an endogenous control. Bottom: western blots were quantified for LC3B-II /GAPDH ratio and the SQSTM1/GAPDH ratio. Data are presented as means ± S.D. * stands for P < 0.05, ** stands for P < 0.01 (n = 3 independent experiments). c Autophagy flux revealed by the mCherry-GFP-LC3 tandem reporter in RAB37 knockdown (miR-RAB37 2#), over-expressed (stably expressing RAB37) and wild-type HeLa cell lines. Representative images of the cells transfected with the mCherry-GFP-LC3 reporter and grown in normal (control), EBSS medium (1 h) or EBSS with bafilomycin A1 (100 nM) addition (1 h) respectively. Single channel (red, green or blue) and merged images were taken by confocal microscopy. d Statistic analysis of vesicles positive for both GFP and mCherry (autophagosomes) and for mCherry (autolysosomes) (>15 cells per experiment) in (c). Percentages of co-localized dots (mCherry-GFP-LC3 (yellow) / mCherry -LC3 (red)) were counted. Data are presented as means ± S.D. * stands for P < 0.05, (n = 3 independent experiments)
RAB37-associated autophagy flux. a, b RAB37 knockdown inhibits and over-expression promotes LC3B-II formation. Bafilomycin A1 treatment results in protein accumulation of LC3B-II and SQSTM1. RAB37 overexpression, RAB37 knockdown and control HeLa cells were cultured and then starved in EBSS with or without bafilomycin A1 (100 nM) for 1 h. The cell lysates were analysed by immunoblotting with antibodies as indicated. GAPDH was used as an endogenous control. Bottom: western blots were quantified for LC3B-II /GAPDH ratio and the SQSTM1/GAPDH ratio. Data are presented as means ± S.D. * stands for P < 0.05, ** stands for P < 0.01 (n = 3 independent experiments). c Autophagy flux revealed by the mCherry-GFP-LC3 tandem reporter in RAB37 knockdown (miR-RAB37 2#), over-expressed (stably expressing RAB37) and wild-type HeLa cell lines. Representative images of the cells transfected with the mCherry-GFP-LC3 reporter and grown in normal (control), EBSS medium (1 h) or EBSS with bafilomycin A1 (100 nM) addition (1 h) respectively. Single channel (red, green or blue) and merged images were taken by confocal microscopy. d Statistic analysis of vesicles positive for both GFP and mCherry (autophagosomes) and for mCherry (autolysosomes) (>15 cells per experiment) in (c). Percentages of co-localized dots (mCherry-GFP-LC3 (yellow) / mCherry -LC3 (red)) were counted. Data are presented as means ± S.D. * stands for P < 0.05, (n = 3 independent experiments)
RAB37 promotes autophagy in vivo
To further investigate the autophagy regulation by RAB37, the stable overexpression and knockdown cell lines were used to implant nude mice. Because autophagy suppression can promote tumorigenesis, [33] we further examined a role for RAB37 in autophagy regulation through tumorigenesis in vivo. Cell counting, scratch migration and soft agar for colony formation assays showed that RAB37 knockdown promoted cell migration and proliferation, whereas RAB37 overexpression had an inhibitory effect (Supplementary Fig. S2b-e). The cells stably expressing RAB37 and miR-RAB37 2# were further used to implant nude mice. After 4 weeks, tumours from both males and females were collected and weighed (Fig. 8a). RAB37 knockdown promoted tumour growth, whereas RAB37 overexpression inhibited tumour growth. Notably, some tumours, when RAB37 knocked down, migrated to other body regions, such as the leg and the back, which indicated that RAB37 deprivation resulted in tumour metastasis. The difference in tumour growth between these two groups was significant (Fig. 8b). Interestingly, the tumour size in females was significantly smaller than in males, indicating a sex-associated regulation of RAB37 in tumour growth. The tumour samples from nude mice were then examined through immunoblotting with anti-LC3B and anti-RAB37 antibodies, which showed that LC3B-II levels decreased in RAB37 knocked-down tumours, whereas LC3B-II levels increased in RAB37-overexpressed tumours (Fig. 8c). Further epithelial-mesenchymal transition (EMT) marker tests showed that β-catenin and N-cadherin were increased in RAB37-knockdown tumours, whereas it was decreased in RAB37-overexpressed tumours (Fig. 8d). Meanwhile, the increase of β-catenin was also obvious in RAB37-knockdown cell cultures (Fig. 8e). Histological and immunofluorescence analysis of tumour samples showed a denser cell growth in RAB37-knockdown than in RAB37-overexpressed tumours (Fig. 8f, g), a phenotype similar to the EMT phenotype. Furthermore, immunofluorescence analysis of clinical tumours samples in humans showed markedly decreased RAB37 expression in prostate adenocarcinomas, prostate transitional cell carcinomas, stomach adenocarcinoma and cervical squamous cell carcinomas (Supplementary Fig. S3a-c). In addition, RAB37 protein was detected in abnormal nuclei in some cervical squamous cell carcinomas (Supplementary Fig. S3c). Taken together, these results suggested that RAB37 promotes autophagy, thus at least partly prevents tumour metastasis.
Fig. 8
RAB37 promotes autophagy in vivo. a Nude mouse experiments. Three cell lines (HeLa cells stably expressing RAB37, miR-RAB37 2# and control cells) were used to implant nude mice. After 4 weeks, the tumours from both males and females were collected. Red arrows show tumour position in mouse. White arrows indicate tumour migration to other places in some mice. b RAB37 knockdown promotes tumour growth. Each bar represents the mean, and the error bars indicate the standard deviation. * stands for P < 0.05. c, d Tumour samples from three types of nude mice were examined through immunoblotting with anti-LC3B and anti-RAB37 (c), anti-β-catenin and N-cadherin antibodies (d). Both β-catenin and N-cadherin are EMT markers. GAPDH was used as an endogenous control. The molecular marker is showed on the left. Bottom: western blots were quantified for the LC3B-II/GAPDH, β-catenin/GAPDH, N-cadherin/GAPDH ratios. Data are presented as means ± S.D. * stands for P < 0.05, ** stands for P < 0.01 (n = 3 independent experiments). e RAB37 interference increases β-catenin protein level in HeLa cell culture in vitro. Bottom: western blots were quantified for β-catenin/GAPDH ratio. f Haematoxylin and eosin staining of three tumour types. Scale bar, 200 nm (up panels) or 100 nm (down panels). Relative cell numbers in one image was quantified. Data are presented as means ± S.D. * stands for P < 0.05, (n = 3 independent experiments). g Immunofluorescence analysis of tumour samples. Arrows show a longer tumour cell morphologically and a denser cell growth in RAB37-knockdown. The tumour sections were immunostained with an anti-RAB37 antibody (FITC). The nuclei were counterstained with DAPI (blue). The images were captured using confocal microscopy. Scale bar, 50 nm
RAB37 promotes autophagy in vivo. a Nude mouse experiments. Three cell lines (HeLa cells stably expressing RAB37, miR-RAB37 2# and control cells) were used to implant nude mice. After 4 weeks, the tumours from both males and females were collected. Red arrows show tumour position in mouse. White arrows indicate tumour migration to other places in some mice. b RAB37 knockdown promotes tumour growth. Each bar represents the mean, and the error bars indicate the standard deviation. * stands for P < 0.05. c, d Tumour samples from three types of nude mice were examined through immunoblotting with anti-LC3B and anti-RAB37 (c), anti-β-catenin and N-cadherin antibodies (d). Both β-catenin and N-cadherin are EMT markers. GAPDH was used as an endogenous control. The molecular marker is showed on the left. Bottom: western blots were quantified for the LC3B-II/GAPDH, β-catenin/GAPDH, N-cadherin/GAPDH ratios. Data are presented as means ± S.D. * stands for P < 0.05, ** stands for P < 0.01 (n = 3 independent experiments). e RAB37 interference increases β-catenin protein level in HeLa cell culture in vitro. Bottom: western blots were quantified for β-catenin/GAPDH ratio. f Haematoxylin and eosin staining of three tumour types. Scale bar, 200 nm (up panels) or 100 nm (down panels). Relative cell numbers in one image was quantified. Data are presented as means ± S.D. * stands for P < 0.05, (n = 3 independent experiments). g Immunofluorescence analysis of tumour samples. Arrows show a longer tumour cell morphologically and a denser cell growth in RAB37-knockdown. The tumour sections were immunostained with an anti-RAB37 antibody (FITC). The nuclei were counterstained with DAPI (blue). The images were captured using confocal microscopy. Scale bar, 50 nm
Discussion
Collectively, we provide direct evidence that RAB37 is linked to autophagy and underlying molecular mechanism. RAB37 is located at the isolation membrane upon autophagy initiation. It interacts directly with ATG5, a key protein at the initiation of pre-autophagosome formation, which recruits ATG16L1 to pre-autophagosomal membranes to form ATG5-ATG12-ATG16L1 complex. Subsequently the complex promotes lipidation of LC3B through a conjugation of phosphatidylethanolamine, thus generating the crucial molecule, LC3B-II, to facilitate the nascent autophagosome genesis. The process is associated with the transition between the active RAB37GTP form and the inactive RAB37GDP form. Nevertheless, RAB37 does not affect degradation process of autophagosomes through lysosomes as revealed by RAB37-associated autophagy flux analysis. Thus, RAB37 is a key organiser of autophagosomal membrane biogenesis at the beginning of autophagy.Over 60 RAB members together with their distinct effectors endow RAB proteins with diversity of functions in vesicle transportation within cells, such as vesicle formation, movement, fusion with other membrane and determining compartment specificity and organelle identity. For example, Rab19 can promote intestinal secretory cell differentiation via regulation of Slit/Robo signalling in Drosophila [13]. RAB33A, an isoform of RAB33 family, participates in regulation of amylase release from parotid acinar cells [34]. RAB33A has also a role in axon outgrowth by mediating anterograde vesicular transport for membrane exocytosis and their concomitant fusion at the growth cones [35]. Several other RAB proteins are involved in autophagy processes [7], such as Ypt1/RAB1 [9], Rab2 [16, 17], RAB7 [36], RAB26 [12] and RAB33 [37], including autophagosome formation and fusion with lysosome at the late stage autophagy. RAB33A/B can interact with ATG16L1 [11] and RAB37 interacts with ATG5 instead of ATG16L1, which indicate that RAB33 and RAB37 are involved in distinct processes in autophagosome formation, probably in different biological activities in particular cell types [38, 39]. RAB37 exerts its function through ATG12-ATG5-ATG16L1 to regulate autophagosome biogenesis in a temporospatial manner. The regulation is dependent on RAB37 ability of GTPases to cycle regularly between GTP- and GDP-bound states, in which RAB37 may act as a timer for on/off regulatory function at the initiation stage of autophagosome formation [40].Because autophagy suppression can promote tumorigenesis [33], an intriguing question is whether RAB37 is involved in tumour suppression by promoting autophagy. This report answers the interesting question. RAB37-knockdown tumours showed tumour migration and an EMT phenomenon in both histological characteristics and EMT markers, indicating a regulatory role of RAB37 in tumour metastasis. These results are consistent with the observation that in certain clinical tumour samples in humans with decreased RAB37 expression, the protein is often translocated into abnormal nuclei. Tumourigenesis is closely associated with autophagy [33]. Some proteins regulate both autophagy and tumorigenesis. For example, ATG6 (BECLIN1) phosphorylation participates in autophagy inhibition and oncogenesis [41]. Previous study showed that RAB37 can suppress metastasis through the TIMP1-MMP9 pathway [30]. RAB37 may exert its tumour suppression role through other processes, such as epigenetic modification [26], in addition to promoting autophagy. As a key organiser of vesicle transport, RAB37 may function in tumorigenesis through exchange of the materials between compartments. Indeed, RAB37 plays a role in exocytosis and secretion [23, 24]. These results indicate that RAB37 may function in multiple molecular processes in regulations of tumour metastasis. RAB37-ATG5 pathway linking to autophagosome formation highlights an importance of intracellular membrane trafficking involving RAB vesicles in maintenance of membrane homoeostasis.Based on these findings, we propose a model to depict a role for RAB37 in autophagosome formation (Fig. 5d). The active RAB37-GTP interacts directly with ATG5, and promotes formation of ~800 kDa multimeric ATG protein complex including eight sets of ATG5-12-16L1. Subsequently, the ATG5-12-16 complex recruits and lipidates LC3B-I to form active LC3B-II, which accelerates autophagosomal formation. RAB37-GTP is then transformed into the inactive RAB37-GDP through the GTPase accelerating protein. Afterwards, RAB37-GDP disassociates from the vesicle membrane and spreads to the cytosol for recycling to organise another initiation process of autophagosomal formation when autophagy induction. Our findings demonstrate a molecular link of RAB37-ATG5-12-16-LC3B-II to autophagosome formation. The molecular mechanism has broad physiological and pathological implications for understanding the role of RAB37 in autophagy promotion, and in particular, cancer prevention and early detection.
Materials and methods
Antibodies and reagents
Primary antibodies: Anti-ATG5 (Cat# 10181-2-AP) was purchased from Proteintech Group, Rosemont, IL, USA. Anti-ATG5 (Cat# ET1611-38) was purchased from HuaAn Biotechnology, HangZhou, China. Anti-ATG5 (Cat# sc-133158) was purchased from Santa Cruz Biotechnology, Dallas, Texas, USA. Anti-ATG16L1 (Cat# 8089) and anti-LC3B (Cat# 3868) were purchased from Cell Signalling Technology, Danvers, MA, USA. The anti-GAPDH antibody (Cat# CW0100A) was from CWBIO, Beijing, China. The anti-β-catenin (Cat# 51067-2-AP), anti-N-cadherin (Cat# 22018-1-AP) and anti-p62 (SQSTM1) (Cat# 18420-1-AP) antibodies were from Proteintech Group, Rosemont, IL, USA. The anti-FLAG antibody (Cat# F3165) and monoclonal anti-LC3B (Cat# SAB4200361, produced in mouse) were from Sigma-Aldrich, St Louis, MO, USA. The anti-MYC (Cat# 11667149001) and anti-GFP antibodies (Cat# 11814460001) were from Roche Applied Science, Indianapolis, IN, USA. The anti-RAB37 antibody was produced by Beijing Protein Institute (Beijing, China) against the peptide C*EPSFQIRDYVESQ in rabbits or purchased from Proteintech Group, Rosemont, IL, USA (Cat# 13051-1-AP).Secondary antibodies: peroxidase-conjugated AffiniPure goat anti-Mouse IgG, light chain specific (Cat# 115-035-174), peroxidase-conjugated AffiniPure F(ab′)2 fragment rabbit anti-mouse IgG, Fcγ fragment specific (Cat# 315-036-046), and peroxidase-conjugated AffiniPure goat anti-rabbit IgG, Fc fragment specific (Cat# 111-035-008) were purchased from Jackson ImmunoResearch Laboratories, West Grove, PA, USA. Goat anti-rabbit IgG, (H + L), horseradish peroxidase conjugated antibody (Cat# 31460), and goat anti-mouse IgG, (H + L), horseradish peroxidase conjugated antibody (Cat# 31430) were from Pierce Biotechnology Company, Rockford, IL, USA.Fluorescein antibodies: FITC-conjugated ImmunoPure goat anti-mouse IgG(H + L) (Cat# ZF-0312), FITC-conjugated ImmunoPure goat anti-rabbit IgG(H + L) (Cat# ZF-0311) and TRITC-conjugated ImmunoPure goat anti-rabbit IgG(H + L) (Cat# ZF-0316) were purchased from Feiyi Technology, Wuhan, Hubei Province, China. AMCA-conjugated AffiniPure goat anti-rabbit IgG (H + L) (Cat# CW0157) was from CWBIO, Beijing, China.Reagent materials: DAPI (Cat# C1002), G418 (Cat# ST081), Hematoxylin Staining Solution (Cat# C0107) and Eosin Staining Solution (Cat# C0109) were purchased from Beyotime Institute of Biotechnology (Jiangsu Province, China). Blasticidine S hydrochloride (Cat# 15205), bafilomycin A1 (Baf A1, Cat# B1793) and GTPγS (Cat# G8634) were from Sigma-Aldrich (St. Louis, MO, USA). Tissue and tumour sections (Cat# MC541, Cat# MBN481) were purchased from US Biomax (Rockville, MD, USA). X-α-gal (Cas# 107021-38-5) was purchased from Gold Biotechnology (St. Louis, MO, USA). Aureobasidin A (Cat# 630466), SD/-Trp supplement (Cat# 630413), SD/-Leu supplement (Cat# 630414), SD/-Leu/-Trp supplement (Cat# 630417), SD/-His/-Leu/-Trp (Cat# 630419) supplement were purchased from Clontech Laboratories, Inc (Takara Bio Company, Kyoto, Japan).
Plasmid constructs
Full-length RAB37 (NM_175738.4) was cloned into pCMV-Tag2B, pSico-Cherry-Flag and pET32a using EcoRI and XhoI to generate FLAG-RAB37, CHERRY-RAB37 and His-RAB37 respectively. Full-length RAB37 was cloned into pEGFP-C1 using XhoI and EcoRI to generate GFP-RAB37. Full-length RAB37 was cloned into pGADT7 using NdeI and BamHI to generate AD-RAB37. FLAG-RAB37, GFP-RAB37, His-RAB37, and CHERRY-RAB37 were used as vector backbone to generate RAB37 mutants (T43N and Q89L) using the primers [18]:T43N5′: 5′-CGTCGGCAAAAACTGTTTCCTGATCC-3′; T43N3′: 5′-GGATCAGGAAACAGTTTTTGCCGACG-3′; Q89L5′: 5′-TGCAGGACTGGAGCGCTTCCGCAGTGTGA-3′; and Q89L3′: 5′-AAGCGCTCCAGTCCTGCAGTGTCCCAG-3′.RAB37-specific (miR-RAB37) or control (miR-lacZ) miRNA target sequences were synthesised and cloned into pcDNATM6.2-GW/Em-GFP-miR containing EGFP and a blasticidin resistance cassette (Invitrogen, Carlsbad, CA, USA). The target sequences for miRNA RAB37 or LacZ were as follows:miR-RAB37 1#: 5′-AGCGTCACCCATGCTTATTAC-3′; miR-RAB37 2#: 5′-GAAAGAGTGATCCGTTCCGAA-3′; and miR-LacZ: 5′-GACTACACAAATCAGCGATTT-3′.Full-length ATG5 (NM_004849.3) was cloned into pcDNA3.0-cMyc using BamHI and XhoI to generate MYC-ATG5. Full-length ATG5 was cloned into pEGFP-N1 and pSico-MYC-GFP using XhoI and BamHI to generate ATG5-GFP and MYC-GFP-ATG5. MYC-GFP-ATG5 was used as a vector backbone to generate ATG5 mutants (MYC-GFP-ATG5-A, MYC-GFP-ATG5-B, MYC-GFP-ATG5-C, MYC-GFP-ATG5-D and MYC-GFP-ATG5-E) using XhoI and BamHI. ATG5 and its mutants were cloned into pGEX-4T-1-GST using BamHI and XhoI to generate GST-ATG5, GST-ATG5-C and GST-ATG5-E, and were cloned into pGBKT7 using NdeI and BamHI to generate BD-ATG5, BD-ATG5-C and BD-ATG5-E. Full-length ATG12 (NM_004707.3) was cloned into pGEX-4T-1-GST using BamHI and XhoI to generate GST-ATG12. Full-length LC3B (NM_022818.4) was cloned into pLove-Red-C1 using BamHI and XhoI to generate RFP-LC3B. Full-length mDFCP1 (NM_021260.3) was cloned into pSico-Cherry-Flag using EcoRI and XhoI to generate CHERRY-mDFCP1.
Cell culture
293T, COS-7 and HeLa cells were cultured in DMEM (Cat# SH30022.01B, HyClone, Logan, USA) with 10% FBS (Cat# P30-330250, PAN-Biotech, Aidenbach, Germany). To establish a stable RAB37-overexpression cell line, HeLa cells were transfected with the FLAG-RAB37 plasmid using FuGENE HD Transfection Reagent (Cat# 04709705001, Roche Diagnostics, Indianapolis, IN, USA). Stably expressing cells were screened using G418 at a final concentration of 800 µg/mL for 4 weeks. To establish stable RAB37 knockdown cell lines, HeLa cells were transfected with miR-RAB37 1# and miR-RAB37 2# plasmids using the FuGENE HD Transfection Reagent. Stably expressing cells were screened using blasticidin at a final concentration of 20 µg/mL for 4 weeks. For starvation treatments, the cells were cultured in EBSS (Cat# SH30029.02, HyClone, Logan, USA) for various times.
Western blot analyses
Western blotting was performed according to routine protocols. The proteins were extracted from 293T cells, HeLa cells or tumours. The whole extracts were analysed using SDS-PAGE and transferred to a 0.45 µm PVDF membrane (Cat# NK0414, Roche Diagnostics, Indianapolis, IN, USA). The membranes were blocked with 5% non-fat dried milk in TBST (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20) and incubated with the antibodies overnight at 4 °C, followed by the horseradish peroxidase-conjugated secondary antibody. The protein bands were visualised by incubating membranes with the ECL Plus detecting reagents (Millipore, Billerica, MA, USA). Band intensity values were obtained using ImageJ (version J2, NIH, Maryland, US). Data were prepared as excel files and analysed by microsoft excel software.
Co-immunoprecipitation assays
To analyse protein interactions in vivo, co-immunoprecipitation assays were performed in 293T and HeLa cells. The cells were starved using EBSS for 1 h before harvest. Cells were lysed in NETN buffer consisting of 50 mM Tris-HCl at pH 8.0, 0.15 M NaCl, 1 mM EDTA, 0.5% NP-40 and a 1x protease inhibitor cocktail (Cat# 04693159001, Roche Applied Science). The cell lysates were incubated with the specified antibody and Protein G Agarose (Cat# 11243233001, Roche) overnight at 4 °C. The resins were collected by centrifugation and then washed five times with NETN buffer. Bound proteins were eluted using loading buffer (50 mM Tris-HCl, 2% SDS, 1% mercaptoethanol, 10% glycerol, 0.1% bromophenol blue, pH 6.8) and separated using 15% SDS-PAGE, followed by immunoblotting with the appropriate antibodies.
Protein purification, protein concentration detection and GTPase assays
BL21 cells were transformed with His-RAB37-wild type, -Q89L or -T43N respectively. Cells were cultured at 37 °C with 220 rpm and induced with 0.1 mM IPTG at 16 °C for 24 h. Supernatants were filtered using 0.22 µm filters, loaded onto Ni NTA Beads 6FF (Cat# P2010, Solarbio, Beijing, China), and then gradiently eluted by five different densities of imidazole (2 µM, 50 µM, 100 µM, 200 µM, 500 µM). Pooled supernatants were dialyzed against lysis buffer (0.1 M Tris/HCl, pH 7.0-8.0) to remove impurity and then concentrated by polyethylene glycol before use.The amounts of recombinant proteins were determined by the Pierce BCA protein assay kit (Cat# 23227, Thermo Scientific, Rockford, IL, USA) according to the manufacturer’s protocol. RAB37 GTPase activity was performed using the QuantiChromTM ATPase/GTPase kit (Cat# DATG-200, BioAssay Systems, Hayward, CA, USA) according to the manufacturer’s protocol.
Sucrose density gradient centrifugation
Three cell lines (RAB37 overexpression, RAB37 knockdown and control HeLa cells) were cultured in DMEM medium with 10% FBS and starved in the medium EBSS for 1 h. The cells were lysed and two hundred microliters of the cell lysates were loaded on the top of continuous sucrose gradients (0–30%). The samples were sedimented at 70,000g for 16 h at 4 °C with a preparative ultracentrifuge (CP80WX, Hitachi, Japan), and then all fractions were collected from the top of the gradient. Fractions were subjected to Western blotting analysis using the indicated antibodies.
Gel filtration
HeLa cell lines (RAB37 overexpression, RAB37 knockdown and control HeLa cells) and two transiently transfected cells (FLAG-RAB37-Q89L, FLAG-RAB37-T43N) were cultured in DMEM medium with 10% FBS and starved in the medium EBSS for 1 h. The cells were lysed and then centrifuged at 50,000g for 30 min. The supernatants (cytosol fraction) were filtered through 0.22 μm filter. Then the fractions were separated by size-exclusion chromatography on a Superose 6 increase 10/300 GL column (Cat# 29-0915-96, GE Healthcare Life Sciences, Fairfield, Connecticut, USA), which has a very broad fractionation range (Mr 5,000–5,000,000), especially for large proteins and complexes, and eluted at a flow rate of 0.5 ml min–1 using the solution (50 mM sodium phosphate, 150 mM sodium chloride, pH 7.2). Fractions were subjected to Western blotting using relevant antibodies. The column was calibrated with gel filtration protein standards (Cat# 28-4038-42, GE Healthcare Life Sciences, Fairfield, Connecticut, USA) containing thyroglobulin (669 kDa), ferritin (440 kDa), aldolase (158 kDa), Conalbumin (75 kDa), Ovalbumin (43 kDa).
Immunofluorescence analyses
COS-7 and HeLa cells were cultured on glass coverslips. At 48 h after transfection using FuGENE HD, the cells were starved in EBSS for 1 h. The tissues were cut using a freezing microtome (Leica, CM1850, Wetzlar, Germany). The cells and tissue sections were fixed with methanol for 20 min at −20 °C and permeabilised with 0.1% Triton X-100 in PBS for 30 min. After treating with 5% BSA for 30 min at room temperature, the samples were incubated with primary antibody overnight at 4 °C. After washing with PBS 5 times, the cells were subjected to indirect immunofluorescence secondary antibody. The nuclei were stained with DAPI. Images were captured with a confocal fluorescence microscope (Olympus, FV1000, Tokyo, Japan).
Immune electron microscopy
HeLa cells were cultured in DMEM medium with 10% FBS. After transfected with pCMV-Tag2B or FLAG-RAB37, the cells were cultured in EBSS for 1 h, fixed with 4% paraformaldehyde and 0.25% glutaraldehyde for 4 h at 4 °C in 0.1 M sodium-phosphate buffer (pH 7.4). For transmission electron microscopy, cell samples were fixed with a 0.1 M sodium-phosphate buffer (pH 7.4) containing 2.5% glutaraldehyde overnight at 4 °C and fixed in 1% osmium tetroxide for 2 h at 4 °C. Following a stepwise ethanol and acetonedehydration and infiltration with Spurr’s epoxy resin, the samples were embedded and polymerized in Spurr’s epoxy resin at 60 °C for 48 h, and then sectioned at a thickness of 70 nm. The samples were blocked for 1 h with 1% BSA (0.05 M TBS, pH 7.4) at 25 °C, incubated with anti-FLAG antibody (0.1% BSA, 0.05 M TBS, pH 7.4) overnight at 4 °C, and washed (0.05 M TBS, pH 7.4) three times at 25 °C. Then the samples were incubated for 2 h at 25 °C with an anti-mouse IgG conjugated to 6 nm gold particles (Cat# 715-195-150, Jackson ImmunoResearch Laboratories, West Grove, PA, USA) (0.1% BSA, 0.05 M TBS, pH 8.2), washed (0.05 M TBS, pH 8.2) four times at 25 °C, and washed three times with miniQ H2O at 25 °C. The samples were double stained with 2% uranyl acetate and Sato’s lead citrate and analysed with JEM-1400 plus transmission electron microscope (JEOL, Akishima, Tokyo, Japan).
Transfection of siRNA oligonucleotides
siRNA oligonucleotides were synthesised from Genepharma, ShangHai, China. siRNA sequences targeting ATG5 [42]: siRNA 1#, 5′-GGUUUGGACGAAUUCCAACUUGUUU-3′; siRNA 2#, 5′-GAUCACAAGCAACUCUGGAUGGGAU-3′ and siRNA 3#, 5′-GCCAUCAAUCGGAAACUCAUGGAAU-3′; negative control RNA, 5′-UUCUCCGAACGUGUCACGUTT-3′. The siRNAs were transfected into HeLa cells using Mission siRNA Transfection Reagent (Cat# S1452, Sigma-Aldrich, St Louis, MO, USA).
GST pull-down assays
BL21 cells were transformed with GST, GST-ATG12, GST-ATG5-WT, GST-ATG5-C, GST-ATG5-E or His-RAB37 respectively. Cells were cultured at 37 °C with 220 rpm and induced with 0.1 mM IPTG at 16 °C for 24 h. Supernatants (GST, GST-ATG12, GST-ATG5-WT, GST-ATG5-C, GST-ATG5-E) were mixed with glutathione-agarose beads (Cat# P2020, Solarbio, Beijing, China) for 4 h at 4 °C. The beads were washed three times with NETN lysis buffer. His-RAB37 supernatants were incubated with 50 µM GTPγS or DMSO control for 4 h at 4 °C. Then the beads were incubated with the supernatants (His-RAB37 + 50 µM GTPγS or DMSO control) and rotated at 4 °C overnight respectively. Finally, the glutathione-agarose beads were washed three times with NETN buffer, denatured by boiling for 10 min, and then subjected to SDS/PAGE and Western blots with antibodies.
Yeast two-hybrid assay
The ATG5 and RAB37 constructs were transformed into yeast strain Y2HGold using the quick and easy yeast transformation mix (Cat# 631851, Clontech Laboratories, Inc. Takara Bio Company, Kyoto, Japan). To test the autoactivation and toxicity, yeast transformed with 100 ng of vectors (BD-ATG5, BD-ATG5-C, BD-ATG5-E) were grown on SD/-Trp/X (SD/-Trp supplemented with 50 μg/mL X-α-Gal), or SD/-Trp/X/A (SD/-Trp supplemented with 50 μg/mL X-α-Gal and 200 ng/mL aureobasidin A) at 30 °C for 2–4 days. Meanwhile, yeasts transformed with 100 ng of vector (AD-RAB37) were grown on SD/-Leu/X (SD/-Leu supplemented with 50 μg/mL X-α-Gal), or SD/-Leu/X/A (SD/-Leu supplemented with 50 μg/mL X-α-Gal and 200 ng/mL aureobasidin A) at 30 °C for 2–4 days. The growth of white colonies on SD/-Trp/X or SD/-Leu/X media and no colony growth on SD/-Trp/X/A or SD/-Leu/X/A plates could indicate no autoactivation and toxicity. Then the constructs were cotransformed into yeasts and were selected on SD/-Leu/-Trp plates. Interaction between two proteins was monitored by growing on SD/-Leu/-Trp/-His plates at 30 °C.
Co-localization analysis
Plasmids with different fluorescence were co-transfected into COS-7, or HeLa cells. Images were taken by the confocal fluorescence microscope (Olympus, FV1000, Tokyo, Japan). Co-localized dots were counted and data were prepared as Excel files. Data were expressed as means ± SD. T-test was used for the statistic analysis. * stands for P < 0.05; ** stands for P < 0.01.
Statistics analysis
The data are presented as the means ± standard deviation. Statistical comparisons were made using Student’s t-test when comparing two groups. One-way analysis of variance (ANOVA) with Tukey’s post hoc test was performed for comparisons among more than two groups. These analyses were performed using the statistical package IBM spss statistics software (SPSS) version 22. For all analyses, a P value < 0.05 was considered to be statistically significant.
Cell proliferation and scratch migration analysis
The cells were cultured in 12-well plates. The cell proliferation rate was determined using a cell counting chamber. Every 12 h, the cells from each well were collected and counted. For scratch migration analysis, the cells were cultured in 12-well plates, and a gap on the surface of the well was scratched with a 10-µl tip. After culturing for 12 h, the relative cell migration distance was used to compare the migration rates between cell lines. Eight tests for every cell line were performed.
Soft agar assay for colony formation
A soft agar assay for colony formation was used to examine the cellular proliferation ability between lines. The cells were cultured between a 0.6% soft agar layer and a 0.35% soft agar layer; all agar layers contained 10% FBS and 100 units/mL penicillin and 100 µg/mL streptomycin. After 2 weeks, the clone size was measured. The total clone numbers and the clone area of each plate were calculated using the software Fuji (Japan).
Tumour xenografts
Three cell lines (RAB37 overexpression, RAB37 knockdown and control HeLa cells) were suspended in normal saline and implanted into nude mice to generate tumours. Five mice per six were prepared for each cell line, and 2 × 106 cells were implanted per mouse. After 4 weeks, the nude mice were sacrificed, and the tumours were collected for subsequent experiments.Supplementary material
Authors: G Ménasché; E Pastural; J Feldmann; S Certain; F Ersoy; S Dupuis; N Wulffraat; D Bianchi; A Fischer; F Le Deist; G de Saint Basile Journal: Nat Genet Date: 2000-06 Impact factor: 38.330
Authors: Dagan Jenkins; Dominik Seelow; Fernanda S Jehee; Chad A Perlyn; Luis G Alonso; Daniela F Bueno; Dian Donnai; Dragana Josifova; Dragana Josifiova; Irene M J Mathijssen; Jenny E V Morton; Karen Helene Orstavik; Elizabeth Sweeney; Steven A Wall; Jeffrey L Marsh; Peter Nurnberg; Maria Rita Passos-Bueno; Andrew O M Wilkie Journal: Am J Hum Genet Date: 2007-04-18 Impact factor: 11.025
Authors: Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong Journal: Autophagy Date: 2021-02-08 Impact factor: 13.391